Last Updated: 02/12/2025
Assessment of P. vivax transmission-blocking activity of novel vaccine candidate (PvGs24)
Objectives
*Original title and text were machine translated from Japanese
This project conducted the assessment of P. vivax transmission-blocking activity of novel vaccine candidate (PvGs24).
Development of a malaria vaccine along with a new antimalarial drug is desired. However, at present, no effective vaccine target has been found. A study was conducted on the transmission-blocking vaccine development targeting PvGs24, which is a novel transmission-blocking vaccine candidate against vivax malaria, in the border area between Thailand and Myanmar. Rabbits were immunized with the recombinant PvGs24 to prepare anti-PvGs24 antibody. A mixture of infected red blood cells collected from a vivax malaria patient in Thailand and anti-PvGs24 antiserum was fed to vector mosquitoes by an artificial blood-feeding method. Approximately 10 days later, the number of oocysts formed on the midgut surface of the mosquito was counted to evaluate the transmission-blocking efficacy of the antiserum. As a result, it was shown that the anti-PvGs24 antibody has a significant transmission-reducing effect in a part of the blood-feeding experiments using anti-PvGs24 antiserum.
Apr 2016 — Mar 2019
$160,066
Related Resources
